<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD010341-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD010341-sec-0022"></div> <div class="table" id="CD010341-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity or oropharyngeal cancers</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Monoclonal antibodies plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br><b>Settings:</b> secondary care<br><b>Intervention:</b> EGFR mAb (either cetuximab or nimotuzumab + either RT or CRT) </p> <p><b>Comparison:</b> RT or CRT alone </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> <p><b> mAb</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Overall survival</b> <br> Followâup: 24â70 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.82</b> <br> (0.69 to 0.97) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>1421<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ</p> <p><b>moderate</b><sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was an 18% reduction in death (during the followâup period) in the participants treated with EGFR mAb therapies in addition to standard therapies </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>133 per 1000 (113 to 156)</p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>347 per 1000 (301 to 396)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>577 per 1000 (515 to 639)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Locoregional control</b> <br> Followâup: 24â70 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.68</b> <br> (0.52 to 0.89) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>424<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>moderate</b><sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was a 32% reduction in recurrence of cancer (during the followâup period) in the participants treated with EGFR mAb therapies (cetuximab) in addition to standard therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>112 per 1000 (87 to 144)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>297 per 1000 (237 to 370)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>510 per 1000 (421 to 607)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Progressionâfree survival</b> <br> Followâup: 24â70 months </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>We formed 2 subgroups: mAb therapy + RT versus RT alone and mAb therapy + CRT versus CRT alone. There was a significant difference between these subgroups (P value = 0.008; I<sup>2</sup> = 86%) and as a result we were unable to pool the data. The subgroup comparing mAb therapy + RT versus RT alone reported a 30% reduction in the number of people whose disease progresses if treated with EGFR mAb in addition to RT (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.006). However, the subgroup comparing mAb therapy + CRT versus CRT alone reported no evidence of a difference in progressionâfree survival (HR 1.08; 95% CI 0.89 to 1.32; P value = 0.76) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>A subgroup estimate shows evidence of an increase in skin toxicity/acneiform rash (all grades of adverse effects: RR 6.56, 95% CI 5.35 to 8.03; 1311 participants, 2 studies; adverse effects grades â¥ 3: RR 17.72, 95% CI 8.33 to 37.73; 1403 participants, 3 studies) in people treated with cetuximab in addition to standard therapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>EGFR:</b> epidermal growth factor receptor; <b>mAb:</b> monoclonal antibody; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5âyear survival data (<a href="./references#CD010341-bbs2-0127">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once for reporting bias (potential publication bias and poor reporting of EGFR and biopsy data in one study).<br><sup>2</sup> Downgraded once due to this being a single study at unclear risk of performance bias. </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD010341-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Tyrosine kinase inhibitors plus standard therapy versus standard therapy alone for the treatment of people with oral cavity and oropharyngeal cancers</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Tyrosine kinase inhibitors in addition to standard treatments for people with oral cavity and oropharyngeal cancers</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br><b>Settings:</b> secondary care<br><b>Intervention:</b> tyrosine kinase inhibitors (erlotinib, gefitinib or lapatinib) + standard therapy (either RT or CRT) </p> <p><b>Comparison:</b> standard therapy (either RT or CRT alone) </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> <p><b> Tyrosine kinase inhibitors</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Overall survival</b> <br> Followâup: 40â60 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.99</b> <br> (0.62 to 1.57) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>271<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2,3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was no evidence of a difference in participant survival in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>159 per 1000 (102 to 239)</p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>402 per 1000 (275 to 557)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>646 per 1000 (478 to 808)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Locoregional control</b> <br> Followâup: 40â60 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.89</b> <br> (0.53 to 1.49) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>271<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2,3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was no evidence of a difference in locoregional control in people treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>144 per 1000 (88 to 229)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>370 per 1000 (241 to 539)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>607 per 1000 (429 to 791)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Diseaseâfree Survival</b> <br> Followâup: 40â60 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 1.51</b> <br> (0.61 to 3.71) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>60<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2,4</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was no evidence of a difference in the length of time that participants survived without signs or symptoms of oral cavity cancer when treated with tyrosine kinase inhibitors (gefitinib) in addition to standard therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>231 per 1000 (101 to 476)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>543 per 1000 (271 to 854)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>795 per 1000 (473 to 980)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Progressionâfree Survival</b> <br> Followâup: 40â60 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.8</b> <br> (0.51 to 1.28) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>271<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2,3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was no evidence of a difference in the length of time that participants stayed alive with stable disease when treated with tyrosine kinase inhibitors in addition to standard therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>130 per 1000 (85 to 200)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>340 per 1000 (233 to 486)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>568 per 1000 (415 to 739)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>A subgroup estimate showed evidence of an increase in gastrointestinal complaints (all grades of adverse effects: RR 15.53, 95% CI 2.18 to 110.55; 67 participants, 1 study) in people treated with lapatinib in addition to standard therapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>CI:</b> confidence interval; <b>CRT:</b> chemoradiotherapy; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5âyear survival data (<a href="./references#CD010341-bbs2-0127">Pulte 2010</a>). </p> <p><sup>1</sup> Downgraded once due reporting bias (data from a large study (<a href="./references#CD010341-bbs2-0005">Gregoire 2011</a>) was not available). </p> <p><sup>2</sup> Downgraded once due to imprecision </p> <p><sup>3</sup> Downgraded once due to unclear risk of bias across multiple domains. </p> <p><sup>4</sup> Downgraded once for applicability â only participants receiving RT as a standard therapy were included in this subgroup (no CRT). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD010341-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Immunotherapy plus standard therapy versus standard therapy alone for the treatment of people with oral and oropharyngeal cancers</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Recombinant Interleukin (rILâ2) in addition to surgery for the treatment of people with oral and oropharyngeal cancers</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with oral cavity or oropharyngeal cancers<br><b>Settings:</b> secondary care<br><b>Intervention:</b> recombinant Interleukin (rILâ2) + standard therapy (surgery) </p> <p><b>Comparison:</b> standard therapy (surgery) alone </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b> Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>No of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> <p><b> Standard therapy</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> <p><b> rILâ2</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Overall survival</b> <br> Followâup: 24â70 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.52</b> </p> <p>(0.31 to 0.87)</p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>201<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There was an 48% reduction in death in the groups treated with rILâ2 in addition to standard therapy </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>87 per 1000<br> (53 to 141) </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>237 per 1000</p> <p>(149 to 363)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>421 per 1000</p> <p>(278 to 599)</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>Diseaseâfree survival</b> <br> Followâup: 24â70 months </p> </td> <td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Lowârisk population*</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p><b>HR 0.66</b> <br> (0.43 to 1.02) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>201<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>ââââ<br><b>very low</b><sup>1,2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="6" bgcolor="#ffffff"> <p>There is no evidence of a difference in the length of time that participants survived without signs or symptoms of cancer when treated with rILâ2 in addition to standard therapies </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>160 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>109 per 1000</p> <p>(72 to 163)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Moderateârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>405 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>290 per 1000</p> <p>(200 to 411)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Highârisk population*</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>650 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>500 per 1000</p> <p>(363 to 657)</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>There was no evidence of an increase or reduction of nausea/vomiting, stomatitis or leukopenia in participants treated with rILâ2 in addition to standard therapy (1 study, 30 participants) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>OIS:</b> optimal information size </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Assumed risk based on 5âyear survival data (<a href="./references#CD010341-bbs2-0127">Pulte 2010</a>) </p> <p><sup>1</sup> Downgraded twice due to high/unclear risk of bias across domains.<br><sup>2</sup> Downgraded once due to this being a single study and due to applicability (only participants receiving surgery as a standard therapy were included in this subgroup (no RT/CRT). </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
